AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Smartwatch and mobile application: Wearing a smartwatch and using a mobile application for one year
Study summary
The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.
Eligibility
Primary outcome measure(s)
- Classification performance of the Parkinson's disease (PD) progression prediction model — Between baseline and 12 months
Classification performance of the model in predicting observed motor disease progression, defined as a binary outcome: the condition of a patient is classified as worsened if either the Movement Disorder Society Unified Parkinson's Disease (MDS-UPDRS) rating scale part III score in ON-state increases by more than 3 points (\>3), or the Levodopa Equivalent Daily Dose (LEDD) increases by more than 10%.
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| University Hospital of Toulouse | Toulouse | France | |
| Technische Universität Dresden | Dresden | Germany | |
| Hospital Ruber Internacional | Madrid | Spain | |
| Queen Mary University of London | London | United Kingdom |
More University Hospital, Toulouse trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07189468 on ClinicalTrials.gov ↗ ← All trials in Spain